Press Releases
- Active Biotech provides status update of its development programs
- Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website
- Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website
- Annual General Meeting of Active Biotech AB
- Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma